LG Chem brings Enbrel biosimilar Eucept to the Korea industry
Date: 2018-06-30   Author: Pankaj Singh  Category: #industry

LG Chem brings Enbrel biosimilar Eucept to the Korea industry

LG Chem, the South Korean chemical behemoth recently announced the launching of Eucept in Korea. Incidentally, Eucept is a biosimilar version of Enbrel which is developed by Amgen and marketed by Pfizer. Enbrel is one of the most purchased drugs in the world, the sale of which amounted to $8.87 billion in 2016, and is liberally used in the treatment of patients with autoimmune diseases like psoriasis, rheumatoid arthritis and other inflammatory conditions.

LG Chem plans to expand its share in the Korea market to worth approximately 20 billion won ($17.8 million) based on strategic competitive differentiation such as securing drug efficacy and safety data through extensive clinical trials and improved injection convenience.

LG Chem confirmed the efficacy of the novel biosimilar and also demonstrated through clinical trials the excellent safety of the product which also includes a notably lower rate of adverse effects of the drug related to the injection sites.

LG Chem held a study for 52 weeks which included 370 patients with rheumatoid arthritis from Japan and Korea to demonstrate the efficacy and safety of the new drug. It also extended its clinical trial by 48 weeks to check the efficacy of the drugs among patients switching to Eucept after using the original drug. The study showed that even if patients switched to using Eucept after using Enbrel for 52 weeks the efficacy of Eucept extended over the 100-week period. The company is also making self-injection of the drug easier and more comfortable for patients with the application of an auto-injection method that uses slimmer needles.

Besides the advanced auto-injection method, LG Chem is hoping to win the market from over its more famed competitor with the affordable pricing of the product which is supposed to be 27% cheaper than the original and other competitor biosimilars. The company explained that a cell culture process with enhanced productivity has contributed towards the its efforts in cost cutting.



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Innovations in surveillance system—a growth enabler in air traffic management
Author: Saipriya Iyer

Transforming air traffic management into a more interoperable, automated, modular and scalable system will potentially reap rewards from developments in virtualization and digital technologies. Seamless high-performing...


Stents industry to witness robust technological innovations with ongoing R&D activities
Author: Pankaj Singh

One of the fastest emerging verticals within the healthcare and medical devices space, the global stents market is set to witness numerous interesting trends in the coming years. Ongoing research and development in the...


Comprehensive Analysis on Bath Fittings and Accesssories Market based on types and application
Author: Ashwin Naphade

The latest Bath Fittings and Accesssories market research added by Market Study Report, LLC, delivers a concise outline regarding the potential factors likely to drive the revenue growth of this industry. The report delivers valuable insights on m...